FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121109442> ?p ?o ?g. }

• W2121109442 endingPage "1754" @default.
• W2121109442 startingPage "1748" @default.
• W2121109442 abstract "Objective This study compared the effects of intraocular injections of ranibizumab (RBZ) and bevacizumab (BVZ) in transgenic mouse models in which human vascular endothelial growth factor (VEGF) causes subretinal neovascularization (NV) or exudative retinal detachment. Design Randomized trials in animal models. Participants Transgenic mice in which the rhodopsin promoter drives expression of human VEGF in photoreceptors (rho/VEGF mice) and double transgenic mice with doxycycline-inducible expression of human VEGF in photoreceptors (Tet/opsin/VEGF mice). Methods Rho/VEGF mice received intraocular injections of RBZ, BVZ, or vehicle, and after various time periods the area of subretinal NV was measured. Tet/opsin/VEGF mice were given an intraocular injection of RBZ, BVZ, or vehicle, and after 5 days of doxycycline treatment the presence or absence of retinal detachment was determined. Main Outcome Measures Area of subretinal NV per retina in rho/VEGF mice and the occurrence of retinal detachment in Tet/opsin/VEGF mice. Results In rho/VEGF mice, intraocular injections of RBZ or BVZ strongly suppressed subretinal NV, but the duration of effect was greater for BVZ. Three injections of 10 μg of BVZ over the course of 2 weeks not only suppressed subretinal NV in the injected eye but also caused significant suppression in the fellow eye, indicating a systemic effect. In doxycycline-treated Tet/opsin/VEGF mice, intraocular injection of 10 μg of BVZ significantly reduced the incidence of exudative retinal detachment compared with injection of 10 μg of RBZ. Injection of 25 μg of BVZ reduced the incidence of retinal detachment in both eyes. Conclusions Intraocular injections of RBZ and BVZ had similar efficacy in rho/VEGF mice, but the duration of effect was greater for BVZ. In Tet/opsin/VEGF mice, in which expression levels of human VEGF are very high and the phenotype is severe, BVZ showed greater efficacy than RBZ. In both models, higher doses or repeated injections of BVZ, but not RBZ, resulted in a systemic effect. These data suggest that BVZ is not inferior to RBZ for treatment of subretinal NV in mice and is superior in a severe model. The systemic effects of BVZ after intraocular injection deserve further study and consideration of their potential consequences. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. This study compared the effects of intraocular injections of ranibizumab (RBZ) and bevacizumab (BVZ) in transgenic mouse models in which human vascular endothelial growth factor (VEGF) causes subretinal neovascularization (NV) or exudative retinal detachment. Randomized trials in animal models. Transgenic mice in which the rhodopsin promoter drives expression of human VEGF in photoreceptors (rho/VEGF mice) and double transgenic mice with doxycycline-inducible expression of human VEGF in photoreceptors (Tet/opsin/VEGF mice). Rho/VEGF mice received intraocular injections of RBZ, BVZ, or vehicle, and after various time periods the area of subretinal NV was measured. Tet/opsin/VEGF mice were given an intraocular injection of RBZ, BVZ, or vehicle, and after 5 days of doxycycline treatment the presence or absence of retinal detachment was determined. Area of subretinal NV per retina in rho/VEGF mice and the occurrence of retinal detachment in Tet/opsin/VEGF mice. In rho/VEGF mice, intraocular injections of RBZ or BVZ strongly suppressed subretinal NV, but the duration of effect was greater for BVZ. Three injections of 10 μg of BVZ over the course of 2 weeks not only suppressed subretinal NV in the injected eye but also caused significant suppression in the fellow eye, indicating a systemic effect. In doxycycline-treated Tet/opsin/VEGF mice, intraocular injection of 10 μg of BVZ significantly reduced the incidence of exudative retinal detachment compared with injection of 10 μg of RBZ. Injection of 25 μg of BVZ reduced the incidence of retinal detachment in both eyes. Intraocular injections of RBZ and BVZ had similar efficacy in rho/VEGF mice, but the duration of effect was greater for BVZ. In Tet/opsin/VEGF mice, in which expression levels of human VEGF are very high and the phenotype is severe, BVZ showed greater efficacy than RBZ. In both models, higher doses or repeated injections of BVZ, but not RBZ, resulted in a systemic effect. These data suggest that BVZ is not inferior to RBZ for treatment of subretinal NV in mice and is superior in a severe model. The systemic effects of BVZ after intraocular injection deserve further study and consideration of their potential consequences." @default.
• W2121109442 created "2016-06-24" @default.
• W2121109442 creator A5037250099 @default.
• W2121109442 creator A5049846578 @default.
• W2121109442 creator A5061061773 @default.
• W2121109442 creator A5071253663 @default.
• W2121109442 creator A5085731729 @default.
• W2121109442 creator A5085965174 @default.
• W2121109442 date "2009-09-01" @default.
• W2121109442 modified "2023-09-24" @default.
• W2121109442 title "Effects of Intraocular Ranibizumab and Bevacizumab in Transgenic Mice Expressing Human Vascular Endothelial Growth Factor" @default.
• W2121109442 cites W1968609549 @default.
• W2121109442 cites W1976384923 @default.
• W2121109442 cites W1981427921 @default.
• W2121109442 cites W1984968613 @default.
• W2121109442 cites W2001343980 @default.
• W2121109442 cites W2023874692 @default.
• W2121109442 cites W2033245558 @default.
• W2121109442 cites W2042523510 @default.
• W2121109442 cites W2042661643 @default.
• W2121109442 cites W2049624292 @default.
• W2121109442 cites W2056553905 @default.
• W2121109442 cites W2058775052 @default.
• W2121109442 cites W2085712747 @default.
• W2121109442 cites W2087780877 @default.
• W2121109442 cites W2091407629 @default.
• W2121109442 cites W2091989599 @default.
• W2121109442 cites W2114615391 @default.
• W2121109442 cites W2124415048 @default.
• W2121109442 cites W2124974853 @default.
• W2121109442 cites W2141508695 @default.
• W2121109442 cites W2141960190 @default.
• W2121109442 cites W2152174806 @default.
• W2121109442 cites W2157769714 @default.
• W2121109442 cites W2233259956 @default.
• W2121109442 cites W4251857773 @default.
• W2121109442 doi "https://doi.org/10.1016/j.ophtha.2009.05.020" @default.
• W2121109442 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2913289" @default.
• W2121109442 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19643496" @default.
• W2121109442 hasPublicationYear "2009" @default.
• W2121109442 type Work @default.
• W2121109442 sameAs 2121109442 @default.
• W2121109442 citedByCount "35" @default.
• W2121109442 countsByYear W21211094422012 @default.
• W2121109442 countsByYear W21211094422013 @default.
• W2121109442 countsByYear W21211094422014 @default.
• W2121109442 countsByYear W21211094422015 @default.
• W2121109442 countsByYear W21211094422016 @default.
• W2121109442 countsByYear W21211094422017 @default.
• W2121109442 countsByYear W21211094422018 @default.
• W2121109442 countsByYear W21211094422019 @default.
• W2121109442 countsByYear W21211094422020 @default.
• W2121109442 countsByYear W21211094422023 @default.
• W2121109442 crossrefType "journal-article" @default.
• W2121109442 hasAuthorship W2121109442A5037250099 @default.
• W2121109442 hasAuthorship W2121109442A5049846578 @default.
• W2121109442 hasAuthorship W2121109442A5061061773 @default.
• W2121109442 hasAuthorship W2121109442A5071253663 @default.
• W2121109442 hasAuthorship W2121109442A5085731729 @default.
• W2121109442 hasAuthorship W2121109442A5085965174 @default.
• W2121109442 hasBestOaLocation W21211094422 @default.
• W2121109442 hasConcept C102230213 @default.
• W2121109442 hasConcept C104317684 @default.
• W2121109442 hasConcept C118487528 @default.
• W2121109442 hasConcept C126322002 @default.
• W2121109442 hasConcept C141035611 @default.
• W2121109442 hasConcept C141071460 @default.
• W2121109442 hasConcept C167734588 @default.
• W2121109442 hasConcept C169760540 @default.
• W2121109442 hasConcept C185592680 @default.
• W2121109442 hasConcept C2776694085 @default.
• W2121109442 hasConcept C2777025900 @default.
• W2121109442 hasConcept C2777093970 @default.
• W2121109442 hasConcept C2777802072 @default.
• W2121109442 hasConcept C2780827179 @default.
• W2121109442 hasConcept C2781100027 @default.
• W2121109442 hasConcept C55493867 @default.
• W2121109442 hasConcept C71924100 @default.
• W2121109442 hasConcept C86803240 @default.
• W2121109442 hasConceptScore W2121109442C102230213 @default.
• W2121109442 hasConceptScore W2121109442C104317684 @default.
• W2121109442 hasConceptScore W2121109442C118487528 @default.
• W2121109442 hasConceptScore W2121109442C126322002 @default.
• W2121109442 hasConceptScore W2121109442C141035611 @default.
• W2121109442 hasConceptScore W2121109442C141071460 @default.
• W2121109442 hasConceptScore W2121109442C167734588 @default.
• W2121109442 hasConceptScore W2121109442C169760540 @default.
• W2121109442 hasConceptScore W2121109442C185592680 @default.
• W2121109442 hasConceptScore W2121109442C2776694085 @default.
• W2121109442 hasConceptScore W2121109442C2777025900 @default.
• W2121109442 hasConceptScore W2121109442C2777093970 @default.
• W2121109442 hasConceptScore W2121109442C2777802072 @default.
• W2121109442 hasConceptScore W2121109442C2780827179 @default.
• W2121109442 hasConceptScore W2121109442C2781100027 @default.
• W2121109442 hasConceptScore W2121109442C55493867 @default.
• W2121109442 hasConceptScore W2121109442C71924100 @default.
• W2121109442 hasConceptScore W2121109442C86803240 @default.
• W2121109442 hasIssue "9" @default.

• next